Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase

Endocrine therapy resistance is a primary cause of clinical breast cancer treatment failure. The p38 mitogen activated protein kinase (MAPK) signaling pathway is known to promote ligand independent tumor growth and resistance to endocrine therapy. In this study, we investigated the therapeutic poten...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Antoon, James W, Bratton, Melyssa R, Guillot, Lori M, Wadsworth, Scott, Salvo, Virgilio A, Elliott, Steven, McLachlan, John A, Burow, Matthew E
Format: Artigo
Sprache:Inglês
Veröffentlicht: e-Century Publishing Corporation 2012
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3410584/
https://ncbi.nlm.nih.gov/pubmed/22860234
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge